SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives
0 references·4 citing·20 second hop
Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives (1985)Hallucinogens: Neurochemical, Behavioral,…The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines (2018)The Varieties of the Psychede…Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action (2007)Further evidence that the del…Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis (2005)Distinct temporal phases in t…Dihydrobenzofuran Analogues of Hallucinogens. 4. Mescaline Derivatives (1997)Dihydrobenzofuran Analogues o…Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents (1984)PIHKAL: A Chemical Love Story (1991)Hallucinogens (2004)Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes (2014)d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology (2016)LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making (2019)Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens (1988)Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis (1997)Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action (1998)An animal model of schizophrenia based on chronic LSD administration: Old idea, new results (2011)Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class (1986)Dark Classics in Chemical Neuroscience: Mescaline (2018)Psychedelics as a novel approach to treating autoimmune conditions (2020)The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects (2021)KNIME - the Konstanz information miner (2009)The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs (2014)Psychedelics (2016)Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives (2019)Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying (2022)Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences (2022)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2005Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis134 cited
  • 1997Dihydrobenzofuran Analogues of Hallucinogens. 4. Mescaline Derivatives90 cited
  • 2018The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines71 cited
  • 2007Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action65 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work